Category Archives: PRNews

PRNews

Frost & Sullivan Commends Oracle’s Expertly Engineered Unified Healthcare Analytics Platform, Oracle Healthcare Foundation

-Oracle Healthcare Foundation is the ideal tool to support the healthcare industry’s current and future data integration and data quality challenges

SANTA CLARA, California, July 19, 2017 /PRNewswire/ — Based on its recent analysis of the health data warehousing market, Frost & Sullivan recognizes Oracle Health Sciences with the 2017 North American Frost & Sullivan Award for Product Leadership. Stepping out of its IT industry stronghold, Oracle has engineered a highly organized version of its data warehouse, Oracle Healthcare Foundation (OHF), for the special needs of the healthcare industry. The solution’s unified analytics platform processes traditional clinical and claims data, financial and operational data and supply chain, human resources, administrative, and operational functions.


Oracle

Oracle Healthcare Foundation is a feature-rich analytics platform that supports more than 35 subject areas relevant to health data analytics, giving healthcare providers more granular data regarding the requirements of individuals and populations. They can use this data to effect process changes and quality improvement initiatives as well as leverage its out-of–the-box self-service analytics tools to build customized analytics solutions.

“The solution’s comprehensive, scalable, end-to-end platform enables data acquisition, validation, integration, warehousing, and analytics. It encompasses all data types and sources, delivering clinical, financial, administrative, and omics modules,” said Frost & Sullivan Principal Analyst for Digital Health Nancy Fabozzi. “It facilitates rigorous data integration, data governance, and data quality, driving greater engagement and adoption by operations, financial management, and clinical care delivery teams across the healthcare enterprise.”

Oracle Healthcare Foundation can be deployed as a complete or modular solution and as an on-premise, cloud, or hybrid solution, all depending on the customer’s unique needs.

“We strive to provide our customers with a range of capabilities that deliver a solid, stable and reliable core data foundation that will enable them to propel their healthcare businesses forward and scale to their future data analytics needs,” said Jonathan Sheldon, Global Vice President, Oracle Health Sciences.

Oracle understands that scientific advancement is resulting in new complex data types such as genome sequencing that need to be incorporated into the data warehouse and made available for clinical decision making. For this to happen successfully, the data warehouse must have the capacity to expand in a way that keeps the data footprint consistent and not leave any gaps. Oracle has made optimum use of its technology expertise and resources to reduce the amount of time and effort needed to set up and maintain a robust data warehouse.

“A stable data warehouse can reduce the effort required to tie together all of the customer’s data resources, normalize data, map new pieces of data or data types, and so on,” noted Fabozzi. “With Oracle Healthcare Foundation, all of this takes place in one stable solution, automated so that relatively few people are required to maintain it once it is set up. In doing so, Oracle allows its customers to shift essential human resources to higher value analytics activities instead of engaging them in connecting a data feed or finding an appropriate analytics application.”

Oracle strives for a very collaborative relationship with its customers and together, they drive the product roadmap. This partnership ensures that as Oracle builds out the data model and requirements, customers stay informed and the solution always meets their needs.

Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Oracle
The Oracle Cloud delivers hundreds of SaaS applications and enterprise-class PaaS and IaaS services to customers in more than 195 countries and territories while processing 55 billion transactions a day. For more information about Oracle (NYSE:ORCL), please visit us at oracle.com.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:
Estefany Ariza
P: 210.477.8469
F: 210.348.1003
E: estefany.ariza@frost.com

PRNews

MyDx Files Complaint Against Former Chief Operating Officer, Protects Unique AeroDx Diagnostic Platform and Addresses Toxic Financier’s Unauthorized Conversion

SAN DIEGO, July 18, 2017 /PRNewswire/ — MyDx, Inc. (OTCQB:MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer initially designed for cannabis professionals and retail consumers to measure the chemicals in cannabis and track their feedback on how each sample is impacting their physiology, today announced that all previously reported variable toxic debts have been satisfied through the unauthorized conversion of the Crown Bridge note and has also filed a lawsuit against its former COO and other defendants who have attempted to create a competitive advantage with its anticipated product launch of its air quality sensor: AeroDx®.


MyDx 2.0 Analyzer with CannaDx and AeroDx Sensor Compatibility

Lawsuit to Protect Unique AeroDx Diagnostic Platform
On July 14, 2017, the Company and its Chief Executive Officer, Daniel Yazbeck, filed a complaint in Superior Court of California against a series of Defendants who have allegedly engaged in unfair business practices, made false statements about the Company, its products, and Mr. Yazbeck at investor events and on online investor platforms.  There can be no assurance about the results or on the outcome of the lawsuit, however, the company took aggressive steps it felt were necessary to protect its business and its shareholders.

AeroDx®: MyDx’s Air Quality Sensor
AeroDx Sensors are the first of three anticipated versatile sensors to be launched into the market and represents the first versatile sensor to be used with the new release of the MyDx 2.0 Analyzer launched in May of this year.  AeroDx is expected to measure key air quality parameters for cannabis and non-cannabis consumers, to be interchanged seamlessly with the CannaDx Sensors. Once AeroDx Sensors are inserted into the MyDx Device, the device becomes an air quality tester with the ability to detect Volatile Organic Compounds (VOC’s) such as Formaldehyde, Butane, Toluene, Methane, Benzene and other harmful chemicals, such as Carbon Dioxide, present in the air. It can also monitor temperature and humidity, which can aid in preventing mold and germ growth. The company is also in the process of customizing the sensor in order to ensure air quality and control in cannabis growth facilities as well offer a test for residual solvents in cannabis oils.

Addressing Remaining Toxic Variable Convertible Debt on Balance Sheet
 On April 30, 2017, the Company sent a payoff demand to Crown Bridge Partners, LLC as required under the terms of the loan Agreement.  The Company agreed to repay, in full, the remaining variable toxic convertible note on its balance sheet prior to the prepayment deadline. Crown Bridge acknowledged the request and despite the Company and its counsel’s repeated payoff request, on July 3, 2017, Crown converted $36,749.04 (the entire amount due pursuant to the Note, including penalties and interest) into 14,699,616 shares of the Company’s common stock. In light of the Company’s notification and Crown Bridge’s acknowledgment required under the terms of the loan Agreements, Crown Bridge executed the conversion and the Company alleges it breached the terms of the Note. The Company will continue to evaluate its rights and determine the best course of action to advance the interests of its shareholders.

As of July 17, 2017, all previously reported variable rate toxic financing has been fully paid off.

About MyDx, Inc.
 MyDx, Inc. (OTCQB: MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology. The MyDx AquaDx®, OrganaDx(TM) and CannaDx(TM) sensors are now commercialized, and the AeroDx® application is next in line. All sensors will be compatible with a MyDx App that empowers consumers to live a healthier life by revealing the chemical composition of what they eat, drink and inhale. For more information, please visit www.mydxlife.com.

Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “intends,” “goal,” “objective,” “seek,” “attempt,” or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov. MyDx is not considered a medical device.  Consumers should be advised that any claims regarding the medical benefits of cannabis are still under research and until approved by the FDA or any other relevant international regulatory body, are considered anecdotal in nature. 

Investor Contact:
MyDx Shareholder Communications
800.814.4550 ext. 4
ir@cdxlife.com

Photo – http://mma.prnewswire.com/media/536158/MyDx_Inc_Analyzer_with_CannaDx.jpg 

Source: MyDx, Inc.

PRNews

CROMSOURCE Celebrates Its 20th Anniversary

VERONA, Italy, July 18, 2017 /PRNewswire/ —

CROMSOURCE marks its twentieth anniversary of providing high quality clinical research services and exceptional customer support to our global pharmaceutical, biotechnology, and medical device clients.

For the last twenty years, CROMSOURCE has been a valued partner to hundreds of global clients, having provided services for more than 3000 clinical trials across a number of important areas. Much of the work which we have performed has led to the approval and marketing of life-changing and life-saving medical products across the globe.

“CROMSOURCE’s twentieth anniversary is an exciting milestone for our company! When I started this adventure, one goal was that CROMSOURCE would become an international provider serving customers all over the world. It is with great pride that today we can say that we have accomplished that ambition,” said Dr. Oriana Zerbini, founder and CEO of CROMSOURCE.

“Moreover, CROMSOURCE could only have achieved such success with the involvement of its employees and clients. We are proud of having the confidence of our clients and being a trusted partner for their product development programs. And, of course, our employees are the heart of our growth and success. Their diligence, motivation, passion, and unwavering dedication have all been a source of inspiration for reaching this important milestone,” continued Dr. Zerbini.

“Looking toward the future, we recognize the need to evolve as the world, and our industry, continues to experience rapid change. Thanks to our talented professionals and flexible approach to performing clinical research services, we are uniquely positioned to be the ideal partner for the most complex and challenging development programs. We also believe the best for CROMSOURCE and our clients and employees is yet to come based on our existing and growing pipeline of opportunities ranging from early phase through post-marketing studies across an important array of therapeutic areas, medical devices, and rare diseases,” said Dr. Troy McCall, Chief Operating Officer stated.

About CROMSOURCE     

CROMSOURCE is an ISO-certified, international provider of outsourced services to the pharmaceutical, biotechnology, and medical device industries, specialized in clinical development and staffing solutions. We  offer a flexible approach to ensure our clients’ unique needs are supported. CROMSOURCE is unparalleled in offering an end-to-end guarantee covering trial timelines, enrollment, and price.  CROMSOURCE operates offices across all regions of Europe and North America. For more information, visit http://www.cromsource.com.

Contact Info
Margherita Mosconi
margherita.mosconi@cromsource.com
+39-045-82-22-811

PRNews

People’s Republic of China Approves Proliant Biologicals for the Importation of New Zealand BSA

ANKENY, Iowa and FEILDING, New Zealand, July 17, 2017 /PRNewswire/ — Following a recent Chinese decision, centered around New Zealand Origin Bovine Material, Proliant Biologicals is now eligible to ship its New Zealand Bovine Serum Albumin (BSA) into the country.  The change comes after months of restricting the importation of any bovine blood products of New Zealand origin into the country.

With the Chinese border now open to Proliant New Zealand and its BSA, it is Proliant’s goal to help support the continued growth of the Chinese Diagnostic, Life Science, Vaccine, and Cell Culture markets, among others.  As the population continues to increase and as more and more Chinese gain access to healthcare, the development of these markets is as vital as ever. 

Proliant Biologicals, and its New Zealand BSA manufacturing facility, is in a unique position to help service the expanding Chinese Life Science industries.  The facility, located in Feilding, is registered with the MPI and is Traceability Certified by the International Serum Industry Association (ISIA).  With dual manufacturing facilities (New Zealand and US), Proliant is the only BSA manufacturer in the world who holds ISIA traceability certificates.

For more information pertaining to Proliant’s New Zealand BSA and its facility, please utilize the following link: http://www.proliantbiologicals.com

Grade

Material Origin

Part Number

Standard Grade pH 7.0

New Zealand

69100

Reagent Grade (Fatty Acid-Free)

New Zealand

Coming Soon

About Proliant Biologicals, Inc.

Proliant is the world’s premier manufacturer of animal extracts and consistent, reliable, traceable Bovine Serum Albumin (Fraction V).  All Proliant bovine albumins are made from Proliant-collected USDA/MPI Edible grade Plasma; and are protease-free, IgG-free, low endotoxin & bioburden with outstanding solubility/filterability characteristics.

Proliant Biologicals is part of the LGI group of companies, premier manufacturer of protein ingredients for food, health, nutrition and biologicals.  Proliant along with American Protein Corporation, BHJ Corporation and Boyer Valley Corporation are privately held companies of the Lauridsen Group Incorporated.

Source: Proliant Biologicals, Inc.

PRNews

Frost & Sullivan Applauds CORAnet™’s Efforts to Strengthen its Brand in the Competitive Mobile Electronic Health Record Market

CORAnet™ Solutions facilitate interoperability across networks and platforms, giving patients and their families ownership and personal control of their medical records

SANTA CLARA, California, July 17, 2017 /PRNewswire/ — Based on its recent analysis of the mobile electronic health record (EHR) market, Frost & Sullivan recognizes CORAnet™ with the 2017 North America Frost & Sullivan Award for Competitive Strategy Innovation and Leadership. CORAnet™ has emerged a successful, cloud-based mobile technology solution provider, offering first responders, doctors, and individual patients 24/7 secure access to personal health records (PHRs). Its advanced software makes possible real-time access to EHR data that is exchangeable along the entire care continuum. This capability is the result of its deep understanding of sophisticated EHR healthcare information technology, health information exchanges, mobile applications, HIPAA and MU3 compliance requirements.

The greater focus on patient engagement due to the shift toward value-based care has heightened the demand for mobile PHR solutions. CORAnet™ has expertly tapped the opportunities in the market by not only delivering novel EHR solutions but also introducing an emergency medicine platform; an ambulatory platform that provides on-demand access to disparate, consolidated and organized PHRs; and a mobile telemedicine platform that offers remote access to care anywhere.

“When using the CORAnet™ solution, individual patients cannot alter any source-identified health information originating from an EHR system. This guarantees data integrity. Users may, however, add or delete diagnosed allergies, thereby safeguarding against contraindications to medications not otherwise annotated,” said Frost & Sullivan Vice President of Global Life Sciences Nitin Naik. “In addition, if the patient wishes to share EHR data using an email address, the system can generate a PDF file that is password protected.”

CORAnet™’s unique mobile solution is enabled by fully interoperable servers that facilitate access to any EHR system, projecting data in a visual, encrypted format. Outstanding features of the CORAnet™ mobile platform include:

  • A patient-facing, EHR-agnostic solution that allows EHR companies, providers, and health facilities to keep their own proprietary data
  • Aggregation of an individual’s PHR from all health system sources into medical data sets such as medical history, x-rays, laboratory results, and plan of care
  • The ability for the patient to update information on vitals, medications, allergies, and dietary supplements consumed

“CORAnet™ has emerged as an innovative technology leader that widens access to PHRs with a system comprising two demonstrative elements: the ability to integrate information from multiple EHR systems, and the ability to deliver an integrated PHR to consumer mobile devices,” said Naik. “These advantages, along with patient engagement capabilities such as appointment setting, reminders, and the option to view and share imaging files, set CORAnet™ apart as an organization that adds significant value in the new field of care collaboration.”

With more sophisticated application providers designing mobile-ready solutions, the mobile “open way” may quickly become the designated entry point for patients and doctors to access personal health data. Frost & Sullivan commends CORAnet™ for delivering a mobile exchange to support interaction, including interoperability, using multiple sensors and monitors.

“Instant access to a patient’s complete health records via CORAnet allows individuals to manage their healthcare, have peace of mind, and can minimize medical errors, hospital readmissions, and reduce costs. For providers, CORAnet is an efficient, economical tool to improve healthcare delivery and outcomes, and compliance with federal Meaningful Use (MU3) mandate for electronic health records (EHR/EMR),” said CORAnet Solutions President & CEO Cora Alisuag.

Each year, Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to successfully execute a competitive strategy that results in stronger market share, competitive brand positioning, and customer satisfaction.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About CORAnet™

CORAnet™ Solutions, Inc. specializes in bringing mobile innovative solutions to the health care industry in the area of health management, electronic health records support, telemedicine and biometrics data predictive analytics.  CORAnet™ addresses the challenge of inefficiencies of health care by providing the interoperability, security, functionality, availability and mobility of health records. Contact us.

Contact:

P: 240 644 1555
E: info@coranetsolutions.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: ana.arriaga@frost.com

PRNews

Mariana Geralde is Recipient of 2017 Basic PDT Research Excellence Award

COIMBRA, Portugal, July 14, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Mariana Geralde was the recipient of the 2017 BASIC PDT RESEARCH EXCELLENCE AWARD.

Mariana Geralde was recognized for research excellence at the Sao Carlos Institute of Physics (Brazil) for her work involving the clinical application of Photodynamic Therapy (PDT) as a method to treat pulmonary infections through extracorporeal illumination. This innovative research has resulted in the significant advancement of both PDT protocols and clinical outcomes, accelerating the potential for PDT treatment of multi-drug resistant pneumonia.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies. The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

please contact: ipasecretary@internationalphotodynamic.com

Logo – http://mma.prnewswire.com/media/535806/International_Photodynamic_Association_Logo.jpg

PRNews

Venus Concept Closes $38 Million Equity Financing to Support Continued Growth Opportunities

TORONTO, July 13, 2017 /PRNewswire/ — Venus Concept Ltd., a privately-held and innovative global aesthetic technology leader, today announced the closing of a $38 million equity investment. The equity investment was led by EW Healthcare Partners along with significant participation from HealthQuest Capital and Madryn Asset Management. This financing will help support the rapid growth of Venus Concept’s industry first and only subscription-based business model, the ongoing expansion and maturation of its 27 direct global offices, and the continued development of products to serve the aesthetic marketplace.

Scott Barry, Managing Director of EW Healthcare Partners, also commented on the investment: “We are pleased to be supporting Dom and the management team of Venus Concept as they continue to successfully expand their product portfolio and services globally. We believe that their differentiated subscription model and unique products positions them well to take full advantage of tailwinds in the non-invasive aesthetic market. We are excited to participate in the growth of the company.”

In conjunction with their investments, EW Healthcare Partners and HealthQuest will each receive one seat on Venus Concept’s board of directors.

Northland Securities, Inc. acted as the sole Placement Agent for this transaction.

About Venus Concept

Venus Concept is a global medical technology company that develops, commercializes, and delivers safe, efficacious, and easy-to-use aesthetic technologies and related practice enhancement services in a unique, industry-disruptive subscription-based business model. Venus Concept’s devices have been designed in cost-effective and proprietary ways that enable the company to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets such as family practice, general practice, internal medicine, obstetrics and gynecology, and medical spas. Approximately 70 per cent of its devices are sold in non-traditional markets. The company has expanded its subscription platform and is now selling its devices in over 60 countries, including 27 with direct offices. The company now has over 400 global employees whose customer-centric approach has supported the rapid growth of the company. For more information, please visit www.venusconcept.com.

About EW Healthcare Partners

With over $3.0 billion under management, EW Healthcare Partners is one of the largest and oldest growth equity firms pursuing investments in pharmaceuticals, medical devices, healthcare services, and healthcare information technology. Since its founding in 1985, Essex Woodlands has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing, and/or management of over 150 healthcare companies, ranging across sectors, stages, and geographies. The team is comprised of over 20 senior investment professionals with offices in Palo Alto, Houston, New York, and London. For more information, please see www.ewhealthcare.com.

About HealthQuest Capital

HealthQuest Capital makes early growth investments in innovative commercial-stage healthcare companies that are improving both patient outcomes and healthcare economics. Investments focus on medical products, diagnostics, healthcare IT, and technology-enabled healthcare services. HealthQuest Capital is headquartered in Menlo Park, CA with west coast and east coast offices. Learn more at www.healthquestcapital.com.

About Madryn Asset Management, LP

Madryn Asset Management, LP is a leading alternative asset management firm that invests in innovative healthcare companies specializing in unique and transformative products, technologies, and services that create attractive economic opportunities. Backed by a seasoned executive management team, the firm draws upon its diverse expertise and original insights to deliver attractive returns for its limited partners while creating long-term value in support of its portfolio companies.

For further information: Melissa Kang, Phone: (888) 907-0115 ext. 139, Fax: (855) 905-0115, Email: mkang@venusconcept.com

Logo – http://mma.prnewswire.com/media/535368/VCO_StandardLogo_BLACK_Logo.jpg

PRNews

Mr. Colin Hopper Receives IPA Lifetime Achievement Award in PDT Clinical Research

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Mr. Colin Hopper was the recipient of the 2017 LIFETIME ACHIEVEMENT AWARD IN PDT CLINICAL RESEARCH.

Mr. Colin Hopper is currently the Senior Lecturer/Consultant Oral and Maxillofacial Surgeon and unit head off oral and maxillofacial surgery at University College London (UCL), Eastman Dental Institute London.  He is a Consultant Head and Neck Surgeon, University College London Hospitals and until recently Senior Research Fellow at the National Medical Laser Centre London.

Mr. Hopper spent his early career pioneering clinical protocols to confirm safety and efficacy of PDT for oncological and antimicrobial applications. Since 1991, Mr. Hopper has been working in the National Medical Centre leading a variety of research projects on the use of photodynamic therapy in the treatment of oral squamous cell carcinoma. This clinical PDT program is currently one of the world’s largest and longest running programs, documenting over 400 treatments involving the three main photosensitizers.

Mr. Hopper, long recognized for his expertise in clinical PDT, is the principal investigator on a series of ethically approved projects, including in a number of developing countries. His work has resulted in numerous publications helping to establish a clear role for PDT treatment in a variety of neoplastic conditions in the head and neck. This work has advanced rapidly by the development of interstitial treatment of tumours using image guidance systems developed with the department of imaging and medical physics.  Other related areas of research include fluorescence diagnostics (optical techniques for tissue interrogation), the use of PDT in the treatment of non-malignant conditions such as lymphangioma and the use of PDT for antimicrobial applications. Mr. Hopper dedicates considerable personal time to lecturing, mentoring and training next generations of PDT clinicians globally.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies.  The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

please contact: ipasecretary@internationalphotodynamic.com

PRNews

Dr. Pilar Acedo Nunez is Recipient of 2017 IPA Early Investigator Award

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Dr. Pilar Acedo Nunez was the recipient of the 2017 IPA EARLY INVESTIGATOR AWARD.

Dr. Pilar Acedo Nunez was recognized for her exceptional research at the University College London (England) involving combination photosensitizers and photodynamic therapy which demonstrated improved efficacy and response rates in vitro and in vivo. She has been awarded several research grants, prizes and awards including a competitive two-year postdoctoral fellowship (2015) sponsored by Ramon Areces Foundation (Spain) and the Peter Samuel Royal Free Trust Fund (UK) to study at UCL under Professor Sandy MacRobert and Professor Steve Pereira.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies.  The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).  

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com

PRNews

Dr. Natalia Inada is Recipient of 2017 Award for PDT Clinical Trial Excellence

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Dr. Natalia Inada was the recipient of the 2017 AWARD FOR PDT CLINICAL TRIAL EXCELLENCE.

Dr. Natalia Inada was recognized for her leadership and fundamental role over a number of innovative Photodynamic Therapy (PDT) based trials at the Institute of Physics of Sao Carlos (Brazil). These multi-centre clinical trials involve hundreds of Latin American patients and relate to the non-surgical PDT-based treatment of skin cancer and the non-surgical PDT-based treatment of cervical intraepithelial neoplasia (CIN), for the prevention of cervical cancer. These Photodynamic treatment protocols are intended to offer minimally invasive, superior outcomes for patients in underdeveloped countries with limited public health systems. Dr. Inada was also the recent recipient of the Mercosul Science and Technology Award for the “CerCa 150 System®: a non-surgical option for cervical intraepithelial neoplasia and condyloma treatment”.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies. The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).  

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com